Baidu
map

Nat Commun:CRISPR系统初步成功清除HIV病毒

2015-03-12 佚名 不详

想象一下,一个成分单一的药物,可以防止人类免疫缺陷病毒(HIV)感染,也能治疗已经感染艾滋病毒的患者,甚至能清除比HIV更厉害的病毒的所有休眠副本。这听起来像科幻小说,但已经有科学家们开始一步步接近于这个目标。他们通过定义和利用细菌和基因剪刀手CRISPR/Cas9系统,为细胞创造了一个新的防御系统。这篇研究成果,发表在最新的Nature Communications。 当HIV病毒复制潜


想象一下,一个成分单一的药物,可以防止人类免疫缺陷病毒(HIV)感染,也能治疗已经感染艾滋病毒的患者,甚至能清除比HIV更厉害的病毒的所有休眠副本。这听起来像科幻小说,但已经有科学家们开始一步步接近于这个目标。他们通过定义和利用细菌和基因剪刀手CRISPR/Cas9系统,为细胞创造了一个新的防御系统。这篇研究成果,发表在最新的Nature Communications

当HIV病毒复制潜入人体细胞,它们就会导致混乱。它使用细胞本身的分子机制制成病毒遗传物质的副本,这些副本随后埋葬细胞自身的基因。从此之后,主体细胞变成一个HIV工厂,使得病毒大量复制,以遍布全身。现有的HIV药物主要瞄准这一生命周期中的各个步骤:比如说一些阻止病毒整合进入细胞的DNA,而另一些尝试包括停止受HIV影响的细胞生产更多的病毒。不过这些药物的问题在于它们不能真正删除那些隐藏在细胞的病毒DNA。这些病毒可以保持休眠状态数年之久,然后再次激活。所以病人通常需要每天或每周的使用药物来保障他们的生活,因为HIV可以潜伏。不过这样花费的金钱,时间和精力实在难以估量。

为了解决这一问题,美国加州La Sierra University的研究人员转向使用CRISPR细菌分子防御系统。细菌可以利用CRISPR系统删除基因中指定地点的外源DNA。最近科学家们已经开始使用CRISPR系统来编辑基因表达。这次研究人员针对的是用CRISPR/Cas9系统切开和破坏人体细胞病毒。

CRISPR/Cas9需要guideRNA来定位它的剪刀位置。科研人员设计了针对HIV病毒guideRNA序列。他们将系统传递进入已经感染了HIV的免疫细胞,发现CRISPR/Cas9系统成功能在设计的位置将HIV基因剪断,并灭活了病毒。这导致了该病毒从72%的感染细胞中完全消失。CRISPR/Cas9系统不仅在最初被感染的细胞中去除了病毒的松散副本,它也同时削减了隐藏在细胞DNA内的处于休眠状态的HIV副本。随后研究人员在多能干细胞内表达了这个CRISPR/Cas9系统,经过工程改造过的干细胞不仅能够稳定的表达靶向HIV的CRISPR / Cas9,高效地分化为HIV reservoir细胞类型,重要的是能够维持对HIV挑战的抵抗,不被感染。

虽然也有其他研究小组采取了类似的办法针对HIV病毒,不过研究人员表示他们的方法能有效打击活跃,全长度的HIV而不是只针对缩短,非活跃的病毒版本。

这一技术的主要优点不仅是消除整合到人基因组病毒DNA,最重要的是,能够预防应用。通过消除处于生命周期早期的病毒,我们或许可以像常规疫苗类似的方式完全防止人细胞对HIV的感染。不过,我们还需要更多的研究来确定如何应用该技术于人类患者;HIV病毒是否会迅速变异,逃避CRISPR系统。考虑到这一点,该团队正在研究增加更多的guideRNA和CRISPR的组合,使得能同时识别病毒的多个DNA位点,增强剪切的有效性。

原始出处:

Liao HK, Gu Y, Diaz A, Marlett J, Takahashi Y, Li M, Suzuki K, Xu R, Hishida T, Chang CJ, Esteban CR, Young J, Izpisua Belmonte JC.Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat Commun. 2015 Mar 10;6:6413. doi: 10.1038/ncomms7413.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086769, encodeId=3a582086e69cc, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Aug 04 23:39:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880539, encodeId=53fc1880539ee, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Apr 09 12:39:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275828, encodeId=dac412e58281e, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412613, encodeId=cb801412613d0, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18201, encodeId=39071820109, content=未来希望所在, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Mar 12 23:50:00 CST 2015, time=2015-03-12, status=1, ipAttribution=)]
    2015-08-04 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2086769, encodeId=3a582086e69cc, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Aug 04 23:39:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880539, encodeId=53fc1880539ee, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Apr 09 12:39:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275828, encodeId=dac412e58281e, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412613, encodeId=cb801412613d0, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18201, encodeId=39071820109, content=未来希望所在, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Mar 12 23:50:00 CST 2015, time=2015-03-12, status=1, ipAttribution=)]
    2015-04-09 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2086769, encodeId=3a582086e69cc, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Aug 04 23:39:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880539, encodeId=53fc1880539ee, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Apr 09 12:39:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275828, encodeId=dac412e58281e, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412613, encodeId=cb801412613d0, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18201, encodeId=39071820109, content=未来希望所在, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Mar 12 23:50:00 CST 2015, time=2015-03-12, status=1, ipAttribution=)]
    2015-03-14 yuandd
  4. [GetPortalCommentsPageByObjectIdResponse(id=2086769, encodeId=3a582086e69cc, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Aug 04 23:39:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880539, encodeId=53fc1880539ee, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Apr 09 12:39:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275828, encodeId=dac412e58281e, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412613, encodeId=cb801412613d0, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18201, encodeId=39071820109, content=未来希望所在, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Mar 12 23:50:00 CST 2015, time=2015-03-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2086769, encodeId=3a582086e69cc, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Aug 04 23:39:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880539, encodeId=53fc1880539ee, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Apr 09 12:39:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275828, encodeId=dac412e58281e, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412613, encodeId=cb801412613d0, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18201, encodeId=39071820109, content=未来希望所在, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Mar 12 23:50:00 CST 2015, time=2015-03-12, status=1, ipAttribution=)]
    2015-03-12 lovetcm

    未来希望所在

    0

相关资讯

Cell:科学家发现可以产生HIV高亲和力抗体的方法

B细胞是人体在生理状态下唯一可以发生体细胞高频突变的场所,而这一过程正是B细胞产生高效抗体的过程。近日,科学家通过在硅载体上的研究发现了可以产生HIV高亲和力抗体的方法。相关研究结果发表于国际生命科学顶尖杂志Cell上。 抗体是由成熟的B细胞或记忆性B细胞分化成浆细胞后分泌产生的免疫球蛋白,可以特异性地结合相应的抗原。亲和力成熟是指浆细胞内基因高频突变从而产生高特异性抗体的过程,是抗体生成所

Nature&STM:黎明前的黑暗?新型长效艾滋病疗法

斯克利普斯研究所近期在Nature上发表最新研究成果,他们报道了一种新型分子eCD4-Ig,有望在无需每日服用抗逆转病毒药物的情况下控制HIV。相比较已知的广谱的HIV抗体,这一分子能更为广泛地攻击HIV病毒株,且效果更佳。此外在40周的研究期间该分子还安全保护了猴子免受了一种HIV类似病毒的感染。 美国国家过敏及传染病研究所(NIAID)主任Anthony S Fauci博士评论这一工作

盘点:基因疗法&HIV疫苗:治愈艾滋的普罗米修斯之火

HIV,即人类免疫缺陷病毒,自其1983年在美国首次发现以来,科学家们便致力于寻找到治愈这一疾病的方法。其中,结合基因疗法的HIV疫苗是诸多研究中很重要也同时很有希望的一个方向。HIV疫苗的研制曾经历尽坎坷,而近期,来自斯克利普斯研究中心的Farzan团队在这方面取得了值得注目的最新进展,再次引起了人们对这一领域的关注。 那么,研制HIV疫苗为何困难重重?科学家们是如何克服这些困难?基因

NEJM:专家指出:与HIV抗争应将战场应从实验室走出去!

近日,一项发表于国际杂志New England Journal of Medicine上的研究报告中,来自阿拉巴马大学的研究者通过研究表示,在对非洲妇女进行的研究中发现,暴露前预防(PrEP)或并不能有效抑制HIV的感染和传播,但实际上这却是研究对象所要面对的影响其机体健康的因素。 “HIV阴性个体可以通过PrEP的方法来降低其被感染的风险,但最好的结果则是通过进行完整过程的坚持服药才可以达到的

LANCET:Sofosbuvir联合利巴韦林可有效治疗 HCV、HIV 共感染患者

尽管不含干扰素的治疗方案已经被批准治疗HIV和2、3型HCV的共感染患者,但是以干扰素为基础的治疗方案对HIV和1、4型HCV型共感染患者来说仍然是的一个常用的选择。然而该方案由于其显著的临床毒性、与抗逆转录病毒药物的相互作用限制了该方案的应用。法国巴黎圣路易斯医院的研究者在 LANCET 2月3日在线发表了一文评估不使用干扰素的情况下、sofosbuvir联合利巴韦林治疗HIV/HCV共感染患者

JAMA:老年患者皮肤及口腔红斑病损伴体重减轻-病例分析

一位74岁英籍男子,4月前发现口腔及颈部、胸部、腹部、上肢处出现暗红色病变,并逐渐增多。在这期间曾到血液科、皮肤科、心内科就诊,被诊断为因华法林抗凝治疗引起的皮肤粘膜瘀斑。患者无恶性肿瘤病史及传染病史。在过去的这几个月里,患者体重减轻15.8kg,否认发烧和夜间盗汗。体格检查发现颈部、躯干及双侧上肢皮肤可见大量微凸的红斑状结节,口内检查可见软腭部存在两处类圆形边界清晰的红色斑块。其余检查未见异常。

Baidu
map
Baidu
map
Baidu
map